These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37407262)

  • 1. White Matter Hyperintensity Trajectories in Patients With Progressive and Stable Mild Cognitive Impairment.
    Kamal F; Morrison C; Maranzano J; Zeighami Y; Dadar M
    Neurology; 2023 Aug; 101(8):e815-e824. PubMed ID: 37407262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topographical differences in white matter hyperintensity burden and cognition in aging, MCI, and AD.
    Kamal F; Morrison C; Maranzano J; Zeighami Y; Dadar M
    Geroscience; 2023 Feb; 45(1):1-16. PubMed ID: 36229760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.
    Cha WJ; Yi D; Ahn H; Byun MS; Chang YY; Choi JM; Kim K; Choi H; Jung G; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY
    Alzheimers Res Ther; 2024 Mar; 16(1):50. PubMed ID: 38454444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
    Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
    J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial hypertension and β-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: a cross-sectional study.
    Bernal J; Schreiber S; Menze I; Ostendorf A; Pfister M; Geisendörfer J; Nemali A; Maass A; Yakupov R; Peters O; Preis L; Schneider L; Herrera AL; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Schott BH; Rostamzadeh A; Glanz W; Buerger K; Janowitz D; Ewers M; Perneczky R; Rauchmann BS; Teipel S; Kilimann I; Laske C; Munk MH; Spottke A; Roy N; Dobisch L; Dechent P; Scheffler K; Hetzer S; Wolfsgruber S; Kleineidam L; Schmid M; Berger M; Jessen F; Wirth M; Düzel E; Ziegler G
    Alzheimers Res Ther; 2023 May; 15(1):97. PubMed ID: 37226207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
    Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
    J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of white matter hyperintensities and regional amyloid deposition on regional cortical thickness.
    Tan CH; Chew J; Zhang L; Gulyás B; Chen C;
    Neurobiol Aging; 2022 Jul; 115():12-19. PubMed ID: 35453034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns.
    Pålhaugen L; Sudre CH; Tecelao S; Nakling A; Almdahl IS; Kalheim LF; Cardoso MJ; Johnsen SH; Rongve A; Aarsland D; Bjørnerud A; Selnes P; Fladby T
    J Cereb Blood Flow Metab; 2021 May; 41(5):1162-1174. PubMed ID: 32955960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
    Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB
    Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid Positivity in the Alzheimer/Subcortical-Vascular Spectrum.
    Kang SH; Kim ME; Jang H; Kwon H; Lee H; Kim HJ; Seo SW; Na DL
    Neurology; 2021 Apr; 96(17):e2201-e2211. PubMed ID: 33722997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
    Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life Span.
    Luo J; Ma Y; Agboola FJ; Grant E; Morris JC; McDade E; Fagan AM; Benzinger TLS; Hassenstab J; Bateman RJ; Perrin RJ; Gordon BA; Goyal M; Strain JF; Yakushev I; Day GS; Xiong C;
    Neurology; 2023 Jul; 101(2):e164-e177. PubMed ID: 37202169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
    Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
    Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linking white matter hyperintensities to regional cortical thinning, amyloid deposition, and synaptic density loss in Alzheimer's disease.
    Zhang J; Chen H; Wang J; Huang Q; Xu X; Wang W; Xu W; Guan Y; Liu J; Wardlaw JM; Deng Y; Xie F; Li B
    Alzheimers Dement; 2024 Jun; 20(6):3931-3942. PubMed ID: 38648354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.
    Lam S; Lipton RB; Harvey DJ; Zammit AR; Ezzati A;
    J Am Geriatr Soc; 2021 Jul; 69(7):1906-1915. PubMed ID: 33891712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. White matter hyperintensities influence distal cortical β-amyloid accumulation in default mode network pathways.
    Ali DG; Bahrani AA; El Khouli RH; Gold BT; Jiang Y; Zachariou V; Wilcock DM; Jicha GA
    Brain Behav; 2023 Oct; 13(10):e3209. PubMed ID: 37534614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden.
    Chan CK; Pettigrew C; Soldan A; Zhu Y; Wang MC; Albert M; Rosenberg PB;
    J Alzheimers Dis; 2022; 86(3):1415-1426. PubMed ID: 35213370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid PET.
    Ottoy J; Ozzoude M; Zukotynski K; Adamo S; Scott C; Gaudet V; Ramirez J; Swardfager W; Cogo-Moreira H; Lam B; Bhan A; Mojiri P; Kang MS; Rabin JS; Kiss A; Strother S; Bocti C; Borrie M; Chertkow H; Frayne R; Hsiung R; Laforce RJ; Noseworthy MD; Prato FS; Sahlas DJ; Smith EE; Kuo PH; Sossi V; Thiel A; Soucy JP; Tardif JC; Black SE; Goubran M;
    Alzheimers Dement; 2023 Apr; 19(4):1503-1517. PubMed ID: 36047604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.